Revenue Cycle Insider

Understand JW and JZ modifiers for accurate oncology billing.

Controlling drug costs has become a major priority for Medicare, especially in oncology, where high‑cost injections and infusions are administered to patients daily. To better track drug utilization and ensure manufacturers refund Medicare for certain discarded amounts, the Centers for Medicare & Medicaid Services (CMS) has tightened its reporting requirements. At the center of this effort are two modifiers every oncology billing professional must understand: JW (Drug amount discarded/not administered to any patient) and JZ (Zero drug amount discarded/not administered to any patient).

Know Why Drug Waste Reporting Matters

The 2021 Infrastructure Investment and Jobs Act requires drug manufacturers to refund Medicare for discarded amounts from refundable single‑dose containers or single‑use package drugs when waste exceeds a defined threshold. To calculate these refunds accurately, Medicare needs reliable data on how much drug is administered versus discarded.

Historically, CMS found that the JW modifier, used to report discarded drug amounts, was not being applied consistently. Missing or inaccurate reporting created gaps in the data needed to determine manufacturer refunds. To solve this issue, CMS introduced modifier JZ to identify when no drug was discarded.

Understand the Difference Between JW and JZ

Chapter 17 of the Medicare Claims Processing Manual outlines the rules for both modifiers:

Modifier JW reports discarded amounts of drugs from single‑dose vials or packages.

• JW is used only when a portion of the drug is not administered to any patient.
• The modifier requires the discarded amount to be billed on a separate claim line from the administered dose.
• This modifier is not used when:
  • The administered dose is less than 1 billing unit (CMS does not accept fractional units)
  • The billing units equal or exceed the actual dose plus the discarded amount
  • There is overfill, which is not billable because it is not an expense to the provider

Modifier JZ was implemented in 2023 to attest that no discarded amount exists.

• The modifier is required on all claims for separately payable Part B drugs from single‑dose containers when zero waste occurs.
• JZ helps CMS distinguish between:
  • Claims missing JW due to oversight, versus
  • Claims where no waste actually occurred.

If a claim is submitted without the required JW or JZ modifier, Medicare will return it as non-processable, according to the Medicare Claims Processing Manual.

View These Key Billing Principles for Single-Dose Containers

Both JW and JZ apply only to drugs in single‑dose vials or packages, as defined by U.S. Food & Drug Administration (FDA) labeling. For multi‑dose containers, providers may bill only the administered amount, as the discarded portions are not separately billable. The discarded amount is defined as the amount that was not administered based on the labeled amount on the vial.

Drug waste cannot be billed if the drug was prepared but never administered, such as when a patient misses an infusion appointment after the medication has already been mixed.

Find Out How to Bill Drug Waste Correctly

When reporting waste from a single‑dose vial:

1. Bill the administered dose on one claim line without a modifier.
2. Bill the discarded amount on a separate claim line with modifier JW.
3. Use modifier JZ on claims where no waste occurred.

Scenario: A patient receives 940 mg of Avastin, coded to J9035 (Injection, Bevacizumab, 10 mg). The drug is drawn from two 400 mg vials and two 100 mg vials, totaling 1,000 mg. In the second, final vial, 60 mg remains and is discarded. Because the discarded amount is clearly identifiable and part of the labeled part of the vial content, JW is required.

Avoid These Common Pitfalls

Oncology practices face unique challenges due to the volume and cost of infused drugs. Misreporting waste can lead to:

• Claim denials
• Compliance risks
• Lost reimbursement
• Incorrect manufacturer refund calculations

Key reminders:

• Never bill overfill. It is not reimbursable.
• Never bill waste for drugs not administered.
• Always use JZ when there is zero waste.
• Always use JW when waste occurs and meets CMS criteria.
• Ensure documentation supports both the administered and discarded amounts.

Consider Commercial Payer Rules

While JW and JZ are Medicare requirements, many commercial payers have adopted similar policies. Practices should verify payer‑specific rules, as modifier usage may vary.

Tell Your Oncology Billing Team Why This Matters

Accurate drug waste reporting is more than a billing formality; it directly affects compliance, reimbursement integrity, and national drug cost‑control efforts. Oncology practices, which routinely handle high‑cost, single‑dose medications, must ensure staff are trained and workflows are updated to meet CMS expectations.

By mastering JW and JZ, billing teams help safeguard revenue, support regulatory compliance, and contribute to Medicare’s broader strategy for managing drug spending.

Nikki Taylor, MSHCI, COC, CPC, CPCO, CPMA, CRC,
AAPC Approved Instructor, McKesson